Table 3. Logistic regression analysis... | American Society of Hematology

Table 3.

Logistic regression analysis for predictors of NIH lung response

Clinical variable		Univariable				Multivariable
Clinical variable		OR	95% CI		P value	OR	95% CI		P value
Belumosudil dose	200 mg QD vs 200 mg BID	1.67	0.49	5.62	.41
	400 mg QD vs 200 mg BID	1.42	0.27	7.52	.68
Age	<50 vs ≥50	0.90	0.30	2.69	.85
Sex	Male vs female	7.22	1.81	28.8	.005	14.07	2.36	83.70	.0037
HLA donor match	Partially matched vs matched	2.31	0.42	12.7	.34
Response to last systemic therapy	PR vs no PR	4.36	1.11	17.2	.036	7.89	1.31	47.71	.024
Conditioning intensity	MAC vs NMA	3.14	0.62	16.0	.17
NIH severity at enrollment	Moderate vs severe	3.23	0.84	12.40	.088	2.80	0.50	15.79	.24
Number of organs involved at enrollment	≥4 vs <4	1.68	0.50	5.61	.4
NIH lung score at enrollment	1 vs (2 or 3)	5.67	1.63	19.70	.006	5.65	1.35	29.60	.028
Time from cGVHD to enrollment in months	<24 vs ≥24	0.73	0.24	2.19	.57
	<36 vs ≥36	1.35	0.44	4.13	.6

Clinical variable		Univariable				Multivariable
Clinical variable		OR	95% CI		P value	OR	95% CI		P value
Belumosudil dose	200 mg QD vs 200 mg BID	1.67	0.49	5.62	.41
	400 mg QD vs 200 mg BID	1.42	0.27	7.52	.68
Age	<50 vs ≥50	0.90	0.30	2.69	.85
Sex	Male vs female	7.22	1.81	28.8	.005	14.07	2.36	83.70	.0037
HLA donor match	Partially matched vs matched	2.31	0.42	12.7	.34
Response to last systemic therapy	PR vs no PR	4.36	1.11	17.2	.036	7.89	1.31	47.71	.024
Conditioning intensity	MAC vs NMA	3.14	0.62	16.0	.17
NIH severity at enrollment	Moderate vs severe	3.23	0.84	12.40	.088	2.80	0.50	15.79	.24
Number of organs involved at enrollment	≥4 vs <4	1.68	0.50	5.61	.4
NIH lung score at enrollment	1 vs (2 or 3)	5.67	1.63	19.70	.006	5.65	1.35	29.60	.028
Time from cGVHD to enrollment in months	<24 vs ≥24	0.73	0.24	2.19	.57
	<36 vs ≥36	1.35	0.44	4.13	.6

BID, twice daily; MAC, myeloablative conditioning; NMA, nonmyeloablative; OR, odds ratio; QD, daily